QuidelOrtho (QDEL)

NASDAQ:QDEL

QDEL

QuidelOrtho

RESEARCH TOOLSreports

Want to see QDEL full AI Analyst Report?

QuidelOrtho (QDEL) Earnings Dates, Call Summary & Reports

Q: When does QuidelOrtho (QDEL) report earnings?

QuidelOrtho (QDEL) is schdueled to report earning on Jul 30, 2026, After Close (Confirmed).

Q: What is QuidelOrtho (QDEL) earnings time?

QuidelOrtho (QDEL) earnings time is at Jul 30, 2026, After Close (Confirmed).

Q: Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

Q: What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

Q: What is QDEL EPS forecast?

QDEL EPS forecast for the fiscal quarter 2026 (Q2) is -0.02.

1,749 Followers

Earnings Data

Report Date

Jul 30, 2026

After Close (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

-0.02

Last Year’s EPS

0.12

Same Quarter Last Year

Analyst Consensus

Hold

Based on 6 Analysts Ratings

Earnings Call Summary

Q1 2026

Earnings Call Date:May 05, 2026|

% Change Since:

Earnings Call Sentiment|Neutral

The call presented a mixed picture: near-term headwinds were significant (a ~30% weaker respiratory season, an 8% decline in labs revenue, quarter-level margin and cash flow pressure, and China distributor pauses), but management emphasized strategic progress—completion of the Lex acquisition, new product launches (troponin, VITROS 450), cost actions, and a full-year plan targeting a 23% adjusted EBITDA margin and positive free cash flow of $100M–$120M. Given the company’s proactive mitigation steps, clear product and pipeline catalysts, and multi-pronged margin initiatives versus the material but largely contextual short-term revenue and cash setbacks, the tone is balanced between caution on near-term execution risks and optimism on medium-term recovery and margin improvement.

Company Guidance

The company updated full‑year 2026 guidance to total reported revenue of $2.0–$2.75 billion, adjusted EBITDA of $615–$630 million (≈23% margin, +100 bps vs. 2025), adjusted diluted EPS of $0.80–$2.00, and free cash flow of $100–$120 million, while modeling an 8% decline in respiratory revenue for the year and saying the midpoint of the revenue shortfall is roughly $75 million (about $45M from weaker respiratory trends and ~$30M from China distributor pauses tied to draft national IVD pricing, which would impact roughly half of China sales); Q1 contextual metrics were revenue $620 million (respiratory $68M, non‑respiratory $552M), labs revenue down 8%, adjusted gross margin 44% (‑630 bps), adjusted EBITDA $109M (18% margin), adjusted diluted loss per share $0.40, operating cash flow ‑$33M, free cash flow ‑$67M, cash $140M and borrowings $130M, and net debt/adjusted EBITDA leverage 4.1x (expected pro forma 3.25–3.5x by year‑end); management expects Q2 roughly flat with Q1 and a stronger second half to drive the full‑year targets.

Completed Lex Diagnostics Acquisition

Acquired Lex Diagnostics (April 2026) adding an ultrafast molecular point-of-care platform; secured initial customer orders, expecting to place a few hundred instruments in 2026 with measurable assay pull-through and associated revenue beginning in early 2027; expanding UK manufacturing capacity to support ramp.

Product Launches and Commercial Traction

Launched high-sensitivity troponin assay in the U.S., now shipping to more than 300 U.S. customers; began rollout of VITROS 450 (CE Mark secured) targeting JAPAC then LATAM/EMEA to support international labs growth; these launches expected to support mid-single-digit revenue growth in the labs business (labs = >50% of revenue).

Q1 Revenue and Non-Respiratory Mix

Total reported Q1 revenue was $620 million with non-respiratory revenue of $552 million ($544 million excluding donor screening), demonstrating diversified revenue streams outside of the respiratory shortfall.

Immunohematology Growth

Immunohematology revenue grew 3% year-over-year, driven by performance in North America, China, and JAPAC.

Cost Discipline and Opex Efficiency

Non-GAAP operating expenses decreased 2% in Q1 driven by R&D efficiencies; company has taken significant cost actions historically (~1,000 positions removed) and outlined procurement, facility consolidation (Raritan shutdown), and targeted staff reductions to drive margin expansion.

Full-Year Profitability and Cash Guidance

Updated full-year 2026 guidance expects adjusted EBITDA of $615 million to $630 million (~23% adjusted EBITDA margin, +100 bps vs 2025), adjusted diluted EPS $0.80 to $2.00, and positive free cash flow of $100 million to $120 million for the year.

Strong Working Capital Actions and FX Tailwind

Delivered strong accounts receivable collections of $54 million in Q1 and reduced CapEx by $22 million versus prior-year; foreign currency was favorable by 210 basis points in the quarter.

QuidelOrtho (QDEL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

QDEL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 30, 2026	2026 (Q2)	-0.01 / -	0.12	―	―	―
May 05, 2026	2026 (Q1)	0.36 / -0.04	0.74	-105.41% (-0.78)
Feb 11, 2026	2025 (Q4)	0.42 / 0.46	0.63	-26.98% (-0.17)
Nov 05, 2025	2025 (Q3)	0.52 / 0.80	0.85	-5.88% (-0.05)
Aug 05, 2025	2025 (Q2)	<0.01 / 0.12	-0.07	271.43% (+0.19)
May 07, 2025	2025 (Q1)	0.59 / 0.74	0.44	68.18% (+0.30)
Feb 12, 2025	2024 (Q4)	0.59 / 0.63	1.17	-46.15% (-0.54)
Nov 07, 2024	2024 (Q3)	0.27 / 0.85	0.9	-5.56% (-0.05)
Jul 31, 2024	2024 (Q2)	-0.23 / -0.07	0.26	-126.92% (-0.33)
May 08, 2024	2024 (Q1)	0.39 / 0.44	1.8	-75.56% (-1.36)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

QDEL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 05, 2026	$11.66	$10.96	-6.00%
Feb 11, 2026	$28.80	$23.73	-17.59%
Nov 05, 2025	$27.37	$21.26	-22.32%
Aug 05, 2025	$23.68	$23.44	-1.01%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.